LMR Partners’s CorMedix CRMD Stock Holding History

LMR Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,517	Closed	-$38K	–	1134
2022 Q3	$38K	Hold	13,517	–	–	﹤0.01%	1120
2022 Q2	$54K	Buy	+13,517	New	+$50.2K	﹤0.01%	1153
2016 Q3	–	Sell	-9,064	Closed	-$90K	–	364
2016 Q2	$90K	Buy	+9,064	New	+$138K	0.01%	406

Other funds holding CRMD

Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

LMR Partners's CRMD Position: Q4 2022 in Review

LMR Partners sold out of CorMedix (CRMD) in Q4 2022, closing a stake of 13,517 shares — an estimated $38K sold.

LMR Partners first reported a position in CRMD in Q2 2016 and held it in 3 quarters. The position peaked at $90K in Q2 2016. 65 funds tracked by Wall St. Rank hold CRMD as of Q4 2022.

LMR Partners reported no remaining CorMedix position as of Q4 2022 after selling out during the quarter.
LMR Partners sold 13,517 CorMedix shares in Q4 2022, an estimated $38K.
LMR Partners first reported a position in CorMedix in Q2 2016 and held it in 3 quarters.
LMR Partners's CorMedix position peaked at $90K in Q2 2016.
65 funds tracked by Wall St. Rank held CorMedix as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.